Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organogenesis Holdings Inc (ORGO)
NASDAQ:ORGO
RESEARCH TOOLSreports
Holding ORGO?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.01Last Year’s EPS
0.02Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 10, 2019
|% Change Since: -3.19%
|Next Earnings Date:Mar 18, 2019
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with revenue exceeding expectations and significant progress in clinical trials. However, challenges such as increased operating expenses and potential market disruptions were also discussed.Company Guidance
During the Q3 2024 earnings call for Organogenesis Holdings, the company provided an updated financial guidance for the year. They projected net revenue between $455 million and $480 million, marking a 5% to 11% increase from 2023. This includes expected revenues from Advanced Wound Care products ranging from $429 million to $452 million (6% to 11% increase) and from Surgical & Sports Medicine products between $26 million and $28 million (a range from a 6% decline to a 1% increase). The company also adjusted their profitability outlook, anticipating a net loss between $12.3 million and $0.6 million, and adjusted EBITDA between $31.7 million and $47.4 million, reflecting an improvement from previous estimates. They highlighted the strong execution of their commercial team, with Q3 net revenue reaching $115.2 million, exceeding their previous guidance of $105 million to $113 million. Additionally, gross profit for Q3 was $88 million, or 76.7% of net revenue, and operating expenses rose by $7.4 million to $82.1 million. The company also secured $100 million from a private placement to support growth initiatives.Revenue Exceeds Expectations
Net revenue for Q3 2024 was $115.2 million, up 6% year-over-year, surpassing the guidance range of $105 million to $113 million.
Advanced Wound Care Growth
Advanced Wound Care net revenue for Q3 2024 was $108 million, up 7% year-over-year.
ReNu Clinical Trial Progress
Completed enrollment of 594 patients for the second Phase 3 trial, exceeding the required 474 patients, with a favorable interim analysis.
Strong Financial Position
Closed a $100 million private placement to enhance balance sheet, supporting strategic growth initiatives.
NuShield Clinical Success
NuShield demonstrated a 48% greater probability of wound closure in a 218-patient study, showing superiority over standard care.
Increased Financial Guidance
Updated 2024 revenue guidance to $455 million-$480 million, up from previous estimates.
---
ORGO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ORGO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $3.45 | $4.43 | +28.41% |
| Aug 08, 2024 | $2.62 | $2.55 | -2.67% |
| May 09, 2024 | $2.28 | $3.03 | +32.89% |
| Feb 29, 2024 | $3.57 | $2.92 | -18.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Organogenesis Holdings Inc (ORGO) report earnings?
Organogenesis Holdings Inc (ORGO) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Organogenesis Holdings Inc (ORGO) earnings time?
Organogenesis Holdings Inc (ORGO) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ORGO EPS forecast?
ORGO EPS forecast for the fiscal quarter 2024 (Q4) is -0.01.
---